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The effects of flavonoids have been correlated with their ability to modulate the
lutamatergic, serotoninergic, and GABAergic neurotransmission; the major targets of
hese substances are N-methyl-D-aspartic acid receptor (NMDARs), serotonin type1A
eceptor (5-HT1ARs), and the gamma-aminobutyric acid type A receptors (GABAARs).
everal studies showed that these receptors are involved in the acquisition and extinction
f fear memory. This study assessed the effects of treatment prior to conditioning with
flavonoid-rich fraction from the stem bark of Erythrina falcata (FfB) on the acquisition
nd extinction of the conditioned suppression following pharmacological manipulations
nd on gene expression in the dorsal hippocampus (DH). Adult male Wistar rats were
reated before conditioned fear with FfB, vehicle, an agonist or antagonist of the 5-HT1AR,
ABAARs or the GluN2B-NMDAR or one of these antagonists before FfB treatment. The
ffects of these treatments on fear memory retrieval, extinction training and extinction
etrieval were evaluated at 48, 72, and 98 h after conditioning, respectively. We found
hat activation of GABAARs and inactivation of GluN2B-NMDARs play important roles
n the acquisition of lick response suppression. FfB reversed the effect of blocking
luN2B-NMDARs on the conditioned fear and induced the spontaneous recovery.
locking the 5-HT1AR and the GluN2B-NMDAR before FfB treatment seemed to be
ssociated with weakening of the spontaneous recovery. Expression of analysis of DH
amples via qPCR showed that FfB treatment resulted in the overexpression of Htr1a,
rin2a, Gabra5, and Erk2 after the retention test and ofHtr1a and Erk2 after the extinction
etention test. Moreover, blocking the 5-HT1ARs and the GluN2B-NMDARs before FfB
reatment resulted in reduced Htr1a and Grin2b expression after the retention test, but
layed a distinct role in Grin2a and Erk2 expression, according session evaluated. We
how for the first time that the serotoninergic and glutamatergic receptors are important
argets for the effect of FfB on the conditioned fear and spontaneous recovery, in which
he ERK signaling pathway appears to be modulated. Further, these results provide
mportant information regarding the role of the DH in conditioned suppression. Taken
ogether, our data suggest that FfB represents a potential therapy for preventing or
reating memory impairments.
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INTRODUCTION
Several studies have investigated the effects of the extracts
of flavonoid-rich plants or flavonoid molecules as potent
modulators of brain structure and function, including their
neuroprotective and chemopreventive properties and their
beneficial effects on memory and cognition. The effects of
flavonoids have been correlated with their ability to modulate the
phosphorylation state of intracellular proteins via the activation
or inhibition of protein kinases and phosphatases (Gamet-
Payrastre et al., 1999; Wang et al., 1999; Schroeter et al.,
2002; Li et al., 2003; Hoffman et al., 2004; Joseph et al.,
2005; Maher et al., 2006; Nakajima et al., 2007; Spencer, 2007;
Vauzour et al., 2008; Williams et al., 2008; Lovera et al.,
2012; Mansuri et al., 2014), to increase the level of 5-HT and
its metabolites (Zhang et al., 2012) or to alter expression of
GABAA receptors (GABAARs) and/or glutamatergic N-methyl-
D-aspartic acid (NMDA) receptors (NMDARs) (Wang et al.,
2005, 2008; Rendeiro et al., 2014). In addition, studies addressing
the effects of specific flavonoid subgroups, including flavanols,
anthocyanins, flavanones, and flavones, have shown that these
constituents display potential to act as cognition-enhancing and
neuroprotective agents (Vauzour et al., 2008; Kehr et al., 2012;
Rendeiro et al., 2013, 2014; Vauzour, 2014), to prevent many
forms of cerebrovascular disease, or to function as anti-anxiety
drugs (Hasenöhrl et al., 1998; Spencer, 2008; Zhang et al., 2012).
Although studies ex vivo, in vivo, and in vitro have provided
evidence supporting the effects of flavonoids on the central
nervous system, the cellular, and molecular pathways through
which these compounds modulate memory formation are not
completely elucidated (Youdim et al., 2004; Nakajima et al., 2007;
Spencer, 2007; Williams et al., 2008; Ballesteros et al., 2014;
Kimura et al., 2014; Rendeiro et al., 2014). However, several
studies have established that the hippocampus, which plays a
central role as a substrate of fear memory and anxiety (Fendt and
Fanselow, 1999; Sanders et al., 2003) and which is a component of
the Behavioral Inhibition System (McNaughton and Gray, 2000),
appears to be a target for the mnemonic effects of flavonoid
metabolites (Bannerman et al., 2004; Wang et al., 2006, 2009;
Williams et al., 2008; Rendeiro et al., 2012, 2014; Oliveira et al.,
2013; Vauzour, 2014).
Previous studies from our laboratory have demonstrated the
role of flavonoid-rich plant extracts, such as a standardized
extract of Ginkgo biloba L. (EGb), in the modulation of fear
memory (Oliveira et al., 2009, 2013) by inducing differential
CREB-1, GAP-43, and GFAP gene and protein expression in
the dorsal hippocampus (DH), the prefrontal cortex and the
amygdaloid complex. Further, we have established that crude
extracts, fractions, and flavonoid molecules isolated from the
stem bark of Erythrina falcata (CE) improved the acquisition
of conditioned fear as evaluated by single-trial, step-down
inhibitory avoidance (IA) (de Oliveira et al., 2014). Additionally,
we used an IA procedure to show for the first time that treatment
with flavones produces another well-established conditioning
phenomenon, spontaneous recovery (de Oliveira et al., 2014).
These findings corroborate with the results described in the
literature and expand the understanding that flavonoids act as
cognition-enhancing agents. However, these results raise new
questions, which are highlighted below.
The first question concerns the anti-anxiety properties
and cognitive effects of the flavonoid-rich fraction from
CE, given the various actions of flavonoids on the central
nervous system. Despite the close relationship between fear
memory and anxiety, these functions are dissociable at the
behavioral, pharmacological, molecular, and neuroanatomical
levels (McNaughton and Corr, 2004; Kalueff, 2007; Nakajima
et al., 2007). The conditioned emotional response (CER)
is a suitable animal model for studying the behavioral,
pharmacological, and molecular mechanisms underlying fear
memory and anxiety. To assess these phenomena, our lab
has used the conditioned suppression of the lick response, in
which the conditional stimulus (CS, tone), when associated with
a noxious unconditioned stimulus (US, footshock), ultimately
suppresses the licking response reinforced by water; i.e., the CS
leads to the suppression of the ongoing behavior (Blanchard
and Blanchard, 1969; Bolles and Collier, 1976; Fanselow,
1980; Sotty et al., 1996; Sanders et al., 2003). Fear responses
(flight/fight/freezing) increase systematically as fear memory
is acquired and decrease as fear memory is extinguished
(Sotty et al., 1996; Liu et al., 2004; Apergis-Schoute et al.,
2005; Davis, 2006; Erlich et al., 2012; Furini et al., 2014).
Conditioned fear responses are insensitive to anxiolytic drugs
(McNaughton and Corr, 2004), but several works show that
treatment with diazepam, an anxiolytic drug that is widely
used in the clinic, prior to the conditioning session disrupts
the initial acquisition of learned fear (Jensen et al., 1979;
Izquierdo and Medina, 1991; Makkar et al., 2010), decreases the
occurrence of freezing responses in a dose-dependent manner
in rats (Fanselow and Helmstetter, 1988; Decker et al., 1990;
Beck and Fibiger, 1995; Malkani and Rosen, 2000; Isoardi
et al., 2004; Yeh et al., 2015) and impairs the acquisition
of conditioned suppression (Oliveira et al., 2009). Anxiolytic
compounds were effective in reducing the inhibitory response of
animals to an aversive stimulus, which alleviated the suppression
of the CER (McNaughton and Gray, 2000; Miyamoto et al.,
2000; George et al., 2009). McNaughton and col. showed that
anxiolytic drugs reduced theta frequency in the hippocampus
(Coop et al., 1991; Munn and McNaughton, 2008). In this
sense, the sensitivity of the CER to anxiolytic drugs, such as
benzodiazepines and agonists of 5-HT1A receptors (5-HT1ARs)
(Millenson and Leslie, 1974; Davis, 1990; Stanhope and Dourish,
1996; Mirza et al., 2005; George et al., 2009; Oliveira et al.,
2009), substantiates the use of this model to investigate the
fundamental mechanisms underlying the effects of anti-anxiety
drugs in addition to their function in alleviating conditioned fear
in rodents.
The second question concerns the neurochemical
mechanisms underlying both the acquisition and the extinction
of conditioned suppression, as well as the role of the flavonoid-
rich fraction from the stem bark of Erythrina falcata (FfB)
in modulating these processes. We primarily focused on the
molecular events underlying the acquisition of fear memory
and the modulatory effects of FfB. Further, we were interested
in determining whether treatment with flavonoids prior to
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conditioning can modulate the extinction process. Studies
demonstrating the involvement of glutamatergic, serotoninergic
and GABAergic neurotransmission in the acquisition of fear
memory have been accumulating in past decades; the major
targets of these neurotransmitters are NMDARs, 5-HT1ARs,
and GABAARs, respectively (Santini et al., 2001; Davis and
Myers, 2002; Lin et al., 2003; Quirk and Mueller, 2008; Kim
and Richardson, 2010), and the modulation of these receptors
in the hippocampus is essential for the acquisition and
consolidation of fear memory (Izquierdo, 1997; Cammarota
et al., 2000; Alonso et al., 2002; Milad et al., 2007). Similarly,
these changes are essential to consolidation of fear extinction
(Myers and Davis, 2002). These effects are mediated by the
activity of kinases and phosphatases, and ERK1/2 activation
has been described to be involved in several cellular changes
associated with long-term memory (LTM) (Atkins et al., 1998;
Cammarota et al., 2000). Blocking NMDARs in the prefrontal
cortex and the hippocampus is known to result in a deficit
in the acquisition of fear extinction (Lissek and Güntürkün,
2003) and the retrieval of fear extinction (Lengersdorf et al.,
2014). Evidence from in vitro and in vivo studies showed
that flavones modulate GABAARs and GluN2B-NMDARs,
but few studies have been conducted on the mechanisms
underlying the modulatory effects of flavonoids on these
processes. Therefore, in our study, we sought to elucidate
the neurochemical systems involved in the acquisition of fear
memory in the presence or absence of FfB treatment and
to determine whether FfB treatment prior to conditioning
modulates the extinction of fear memory. Further, we evaluated
how these changes may control or be controlled by the activation
or inhibition of specific receptors using pharmacological agonists
or antagonists.
Therefore, the contributions of the glutamatergic,
serotoninergic, and GABAergic systems, as well as the
interactions between these systems, to the effects of FfB on
the acquisition and extinction of conditioned suppression were
assessed for the first time by administering agonists, antagonists
of receptors for GABA, glutamate (NMDA) and 5-HT or one
these antagonists before FfB prior the conditioning session.
Additionally, we evaluated the mRNA expression levels of the
GluN2A and GluN2B subunits of the NMDAR, the receptor
subunits GABAAR and 5-HT1AR and ERK1/2 in the DH of
controls and treated rats subjected to acquisition and extinction
of conditioned fear.
This combination of molecular, behavioral and
pharmacological analyses advances our understanding of
the role of flavones in fear memory and anxiety. The findings
regarding the molecular mechanisms of flavone action appear
to be promising with respect to the development of new
therapeutic strategies for the treatment of cognitive deficits or
anxiety disorders. Moreover, we assessed the contribution of the
hippocampus to these processes. In particular, we focused on
the suppression of the licking response as a behavioral model
and the hippocampus as a key component of the neural circuitry
involved in the acquisition, consolidation and extinction of
fear memory in animals and humans, as the hippocampus may
represent a target for the action of FfB.
EXPERIMENTAL PROCEDURES
Drugs and Reagents
Methanol (HPLC grade) was obtained from Merck (Darmstadt,
Germany). Formic acid, ethanol, n-butanol, and Tween R©-80
were obtained from Synth (Diadema, Brazil). Vitexin and
isovitexin standards (99.99%) were purchased from Sigma-
Aldrich (São Paulo, Brazil). The 6-C-glycoside-diosmetin and
vicenin-2 standards were generated in our laboratory according
to the methods described by de Oliveira et al. (2014). Valium R©
(diazepam) was purchased from Roche (São Paulo, Brazil).
Sintocalmy R© (standardized extract of Passiflora incarnate L.—
extract ACH 06) was obtained from Aché (Guarulhos, Brazil).
Ro25-6981, picrotoxin and (S)-WAY100135 were purchased
from Tocris Biosciences (Ellisville, MO, USA). NMDA was
obtained from Sigma-Aldrich (São Paulo, Brazil). Buspirone
hydrochloride was obtained from LIBBS Pharmaceutical Ltd (São
Paulo, Brazil).
Standardized FfB Preparation
FfB was obtained by flash chromatography, as previously
described by de Oliveira et al. (2014). Additionally, the FfB
was analyzed using high-performance liquid chromatography
(HPLC) combined with electrospray ionization tandem mass
spectrometry (HPLC-ESI/MSn) using a Thermo LCQ Fleet
System mass spectrometer (Thermo Scientific, San Diego, CA,
USA) equipped with an electrospray interface (ESI) and an
HPLC (model Accela, Thermo Scientific). FfB separation was
performed using a Luna R© C18 column (250 × 4.60mm;
Phenomenex, Torrance, CA, USA) at room temperature. The
mobile phase consisted of 0.1% aqueous formic acid-water
(A) and methanol (B). A gradient elution method of A/B
(from 64:36 to 1:1, v/v) was applied over 50min. Ultraviolet
(DAD) detection was performed at 330 nm; the flow rate was
maintained at 0.8mL/min; the sample concentrations were 1
mg.mL−1; and the injection volume was 10µL. The column
eﬄuents were analyzed by ESI-MS in negative ion mode in
the mass-to-charge ratio (m/z) range of 50–2000, with a scan
time of 0.3 s in the centroid mode. The ESI conditions were
as follows: nebulizer gas (nitrogen), 30 psi; drying gas, 60
L.min−1; drying temperature, 280◦C; capillary voltage, 4000V;
collision gas, nitrogen; and collision energy,1V. The data were
acquired in the MS and MSn scanning modes. The CE was
dissolved in H2O: MeOH (1:1v/v) and was infused directly
via a syringe pump (flow rate 5µL.min−1) in the ESI source.
The data were analyzed using Xcalibur 2.0 Software R© (Thermo
Scientific).
The flavonoids present in the FfB were quantified by HPLC-
DAD using a Luna R© C18 column (Phenomenex, Torrance,
CA, USA; 250mm × 4.60mm, 5µm). The mobile phase
consisted of 0.1% aqueous formic acid (A) and methanol (B).
An isocratic elution method of A/B (64:36, v/v) was applied for
50min. UV spectra were recorded from 200 to 400 nm, and the
chromatogram was monitored at 254, 280, and 330 nm. The flow
rate was maintained at 1mL.min−1; the sample concentration
was 1mg.mL−1; and the injection volume was 20µL. Analytical
curves were obtained for vitexin, isovitexin, vicenin-2, and
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6-C-glycoside-diosmetin (1mg.mL−1 of each compound in 80:20
methanol/water), which peaked at concentrations ranging from
100 to 1.000mg.mL−1. The sample peak areas were integrated at
254 nm. All of the procedures were performed in triplicate.
Behavioral and Pharmacological Effects of
Acute Treatment with FfB Before
Conditioning on the Acquisition and
Extinction of Conditioned Suppression
Subjects
A total of 470 adult maleWistar rats (±250–300 g) were obtained
from the Center for the Development of Experimental Medicine
and Biology (CEDEME, Federal University of Sao Paulo, SP,
Brazil). The rats were housed 5 animals/cage. For 15 days,
the animals had free access to food and water under a 12
h:12 h dark:light cycle (lights on at 6:00–18:00 h) at a controlled
temperature (21◦C ± 2◦C) and relative humidity (53 ± 2%).
These conditions were maintained throughout the experimental
period. One minute prior to the experimental sessions, each
rat was placed in an individual cage for transportation to
the testing room. All of the procedures for manipulation of
the animals were consistent with the Ethical Principles in
Animal Research adopted by the Brazilian College for Animal
Experimentation (COBEA) and were performed as suggested
by the APA Guidelines for Ethical Conduct in the Care and
Use of Animals. The protocol was approved by the Committee
on the Ethics of Animal Experiments of the Federal University
of Sao Paulo (Permit Number: 840560). After completion of
the behavioral experiments, the animals were decapitated, and
the DH was extracted within 40–60 s using a magnifying glass,
immediately frozen on dry ice, and maintained at −80◦C
until gene expression analysis. All behavioral procedures were
conduced during the light phase of the dark:light cycle, and all
efforts were made to minimize suffering.
Systemic Administration
Diazepam and buspirone hydrochloride (a GABAAR and a
5-HT1AR agonist, respectively), Sintocalmy
R©(a standardized
extract of Passiflora incarnata L.-extract ACH 06, containing
7% (21mg) total flavonoids expressed as vitexin) and three
different concentrations of FfB were dissolved in 12% Tween R©-
80 and administered orally via intragastric gavage (IG) 30min
before each conditioning session. The GABAAR, 5-HT1AR, and
GluN2B-NMDAR antagonists (picrotoxin, S-WAY 100135 and
Ro25-6981, respectively) and NMDA (an NMDAR agonist) were
dissolved in saline and injected intraperitoneally (i.p.) 20min
before each conditioning session or prior to treatment with
FfB. When an antagonist was administered before with FfB, the
drugs were administered −50 or −30min before conditioning,
respectively. No drugs were administered before the retention
test, extinction training or the extinction retention test. The
drugs were administered i.p. or IG in a volume of 1mL. The
doses, administration routes and vehicles used to dissolve of the
antagonists and agonists were chosen based on previous reports
(Aguilar et al., 1997; Risbrough et al., 2003; Oliveira et al., 2009).
Experimental Procedure
Rats were randomly assigned to the control group or the FfB
group (n = 20 per subgroup) (Table 1). The control group was
subdivided into 12 subgroups as follows: (i) the paired stimulus
conditioned/unconditioned stimulus (CS-US) subgroup; (ii)
TABLE 1 | Experimental groups.
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the unconditioned subgroup [no footshock, i.e., only tone (CS);
as such, these animals were used as controls for learning];
(iii–iv) the negative control subgroups (12% Tween R©-80 or
saline); (v–xi) the positive control subgroups (4.0 mg.Kg−1
diazepam; 10.0mg.Kg−1 NMDA; 10.0mg.Kg−1 buspirone
hydrochloride; 600 mg.Kg−1 Sintocalmy R©; 0.75mg.Kg−1
picrotoxin; 3.0 mg.Kg−1 Ro25-6981; or 0.3mg.Kg−1 (S)-WAY
100135; these animals were used as controls for treatment
with the respective drug together with FfB); and (xvii) a naïve
subgroup (n = 10), which was used as a control for gene
expression. The FfB groups were also divided into 12 subgroups
as follows: (xiii–xiv) FfB alone (0.15 mg.Kg−1 FfB, 0.30mg.Kg−1
FfB or 0.65mg.Kg−1 FfB); (xv–xvii) picrotoxin+FfB (Picro+
0.15mg.Kg−1 FfB; Picro+0.30mg.Kg−1FfB; or Picro+0.65
mg.Kg−1 FfB); (xviii–xx) Ro25-6981+FfB (Ro+0.15mg.Kg−1
FfB; Ro+0.30mg.Kg−1 FfB or Ro+0.65mg.Kg−1 FfB); and (xxi–
xxiii) (S)-WAY+FfB [(S)-WAY+0.15mg.Kg−1 FfB; (S)-WAY+
0.30mg.Kg−1 FfB or (S)-WAY+0.65mg.Kg−1 FfB]. Half of the
rats (n = 10/subgroup) were sacrificed after the retention test
ended. The remaining half (n = 10/subgroup) were subjected to
extinction training and an extinction retention test of the CER
and were sacrificed 3 h after the conclusion of the extinction
retention test.
Behavioral Apparatus
Rats were fear conditioned in a lick-operant chamber. Briefly, the
experimental chambers consisted of an aluminum (side walls)
and Plexiglas (ceiling and hinged front door) box measuring
25×25× 20 cm set inside a sound-attenuation cabinet (53×65×
50 cm). Three identical chambers and cabinets were used in all
experiments. The floor consisted of stainless steel rods connected
to grid shockers (model EP 107R, Insight, Ribeirão Petro, Brazil)
set to deliver 0.4mA, 0.5 s scrambled shocks, which were used
as the US. A speaker positioned on top of the square, which
produced a 2 kHz, 85 dB sound for 30 s, was used as the CS. A
licking spout was slipped into the cage through a hole in the
middle of the wall of the chamber; this hole protruded from the
lateral wall 5.0 cm above the grid floor. Stimulus presentation
and data recording were controlled using software (Refor II
Software R©, Insight) and a central controller box (Insight). The
chambers were cleaned with 10% ethanol before each test.
Behavioral Procedure
The behavioral procedure was conducted for 8 or 10 days,
according to the experimental design, to assess the acquisition or
extinction of a CER, respectively. All rats, except for those in the
CS and naïve subgroups, were subjected to a procedure to induce
acquisition of fear memory (n = 20/group) (Figure 1). Three
hours after the completion of the fear acquisition test (8th day),
half of the rats were decapitated. Then, the DH was extracted
within 40–60 s using a magnifying glass, immediately frozen on
dry ice, and maintained at −80◦C until gene expression analysis
(acquisition analysis) (n = 3/subgroup). The remaining half of
the animals (n = 10/subgroup) were subjected to extinction
training (9th day) and an extinction retention test (10th day)
performed on each of the two consecutive days following the
acquisition test. Three hours after completing the extinction
retention test, these rats were decapitated, and the DH was
extracted as described above (n = 3/group).
Suppression of the licking response
The animals were deprived of water on a daily basis for 12–16 h
before all experimental sessions. For five consecutive days, the
rats were placed individually in the chamber once a day for
20min sessions with free access to the drinking spout to obtain
a stable baseline of drinking behavior, but no other stimuli
were presented (Figure 1A). After the administration of drugs
or vehicle, each rat was gently placed in the experimental
chamber, and after 5min, the animal was submitted to four tone-
shock (CS-US) pairings (fear conditioning, 6th day; Figure 1B).
Twenty-four hours after fear conditioning, the animals were
subjected to reacquisition of the licking response sessions (7th
day) as performed during the acquisition of the licking response
to re-establish drinking behavior after conditioning and to reduce
FIGURE 1 | Schematic outline of the experimental procedure and drug administration time, common to all animals, except for the CS-US, and CS
groups, in which did not receive the drug or vehicle. (1A) The animals were submitted to acquisition of the licking response for 5 days (baseline behavior). (1B)
On day 6, the animals were submitted to four associations of CS-US (conditioning). (1C) Twenty-four hours later (day 7), the animals were submitted to re-acquisition
of licking behavior, in conditions identical to those of the acquisition period (1–5 days). Retention Test (1D), Extinction Training (1E), and Extinction Test (1F) were
performed on days 8, 9, and 10, respectively. Ten CS trials were presented at these times. No drugs were administered during the tests and extinction training sessions.
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contextual cues (Figure 1C). The retention test was performed
48 h after acquisition (8th day) to evaluate the acquisition of
fear memory as well as the effects of drug treatment. Here, each
rat was placed in the experimental chamber with free access to
the water spout and was subjected to the CS on 10 consecutive
trials, in which the time to complete 10 licks pre-tone (no CS)
and during the tone (CS) were recorded, and the suppression
ratio (SR) was calculated for each trial. The tone was presented
immediately after the animal completed its 90th lick and was
switched off after its 100th lick (Figure 1D). The latency to
complete licks 0–80 was recorded to ensure that the rats were
licking when the tone was presented, but this value was not used
to calculate the suppression of the lick response. The latency to
complete licks 81–90 was measured as a control for time in the
absence of a tone and was used to calculate the SR.
Therefore, the SR was calculated as the ratio of B/(A+B)
for each rat, where A is the time to complete 10 licks pre-tone
(pre-CS), i.e., time to complete licks 81–90 and B is the time
to complete 10 licks during the CS, i.e., time to complete licks
91–100.
Extinction of suppression of the licking response
Analysis of the effects of FfB on extinction was performed using
the behavioral protocol described for acquisition. All rats were
subjected to tests of adaptation (1st–5th days), acquisition (6th
day), reacquisition (7th day), and retention of the CER (8th day).
Seventy-two hours (9th day) and ninety-six hours (10th day)
after fear conditioning, the rats were placed in the experimental
chamber for extinction training and extinction test sessions,
respectively (Figures 1E,F). In both sessions, the latencies to
complete licks before the tone and during the tone for 10
consecutive CS presentations were recorded as described for the
8th day.
Data Analysis
The data from the first CS presentation indicated whether
the association was learned. An SR approaching 1.0 indicates
total suppression (high fear), whereas an SR ≤0.5 indicates
no suppression (low fear), i.e., failure to learn the tone-shock
relationship. The data are reported as the means ±SEM. A Two-
way analysis of variance (ANOVA) was used to test for the
presence of the effects of group and trial and the interaction
between these variables; two fixed factors (group and trial), one
random factor (rat), and repeated measurement of the trials were
considered. P < 0.05 were considered significant. Graph Pad 6.0
Software R© (version 6.0; Graph Pad Inc., San Diego, CA, USA)
was used for data analysis.
Expression of Gabra5, Htr1a, Grin2a,
Grin2b, and Mapk1/Erk2 by Quantitative
PCR (qPCR) Following Treatments Before
Conditioning and Behavioral Analysis
The analysis of gene expression in the DH samples was
extracted 3 h after the completion of the retention test or the
extinction retention test as previously described. The candidate
genes gamma-aminobutyric acid receptor subunit alpha-5
(Gabra5), 5-hydroxytryptamine (serotonin) receptor, subunit
1A (Htr1a), glutamate receptor ionotropic, NMDAR subunit
GluN2A (Grin2a), glutamate receptor ionotropic, NMDAR
subunit GluN2B (Grin2b), and extracellular signal-regulated
kinase 2 (Erk2) were investigated. To this end, total RNA was
isolated using Trizol reagent (Invitrogen Corp., Carlsbad, CA,
USA) according to the manufacturer’s recommendations. One
microgram of total RNA was subjected to DNA-free DNase
treatment (AMBION, Austin, TX, USA) and reverse-transcribed
into cDNA using the SuperScript R© III Reverse Transcriptase kit
(Invitrogen Corp.) together with oligo12−18 primer and 10 units
of an RNase inhibitor (Invitrogen Corp.). Reverse transcriptase-
negative samples were prepared for each individual reaction and
were used as controls for assay contamination. Aliquots of 1µL
of cDNA were used in 12µL reactions containing SYBR Green
Master Mix (PE Applied Biosystems, Foster City, CA) and 3pM
of each primer for the target genes and the reference gene (RS8) as
described previously (Cerutti et al., 2004). The primer sequences
are displayed in (Table S1). The qPCR reactions were performed
in triplicate, and the threshold for each cycle (Ct) was obtained
using Applied Biosystems software (Applied Biosystems) and
averaged [standard deviation (SD)≤ 1]. Relative expression (RE)
levels were calculated using the 2−△△CT method (ddCt formula)
as described previously (Cerutti et al., 2004). The vehicle (12%
Tween R©-80 or saline) was used as a control.
The analyses were performed using Graph Pad 6.0 Software R©
(version 6.0; Graph Pad Inc., San Diego, CA, USA). For candidate
gene expression analysis, normality of the data was verified using
the Shapiro-Wilk normality test. One-way ANOVA followed
by a post-hoc Bonferroni test was performed to evaluate the
relationships between the expression levels of Gabra5, Htr1a,
Grin2a, Grin2b, and Erk2 across groups. P < 0.05 were
considered significant.
RESULTS
Identification of Flavonoids in FfB
The spectroscopic and chromatographic data of the peaks (1–
6) of the FfB are summarized in Figures S1A,B. The identities,
fragmentation patterns and UV spectra were confirmed as
follows: (1) vicenin-2:λmax = 334, 271 nm, [M-H]− = m/z
593; (2) vicenin-1:λmax = 332, 271 nm, [M-H]− = m/z 563;
(3) vitexin:λmax = 269, 235 nm, [M-H]− = m/z 431; (4)
isovitexin:λmax = 335, 271 nm, [M-H]− = m/z 431; (5) 6-C-
glycoside-diosmetin:λmax = 342, 270 nm, [M-H]− = m/z 461;
and (6) apigenin:λmax = 305, 265 nm, [M-H]− = m/z 269.
These results were consistent with those previously reported by
de Oliveira et al. (2014). The identification of 6-C-glycoside-
diosmetin, vicenin-2, vitexin and isovitexin was supported by
the co-injection of the standards and FfB. The flavones (1, 3,
4, and 5) found in the FfB were quantified by HPLC-DAD,
and the concentrations contained in the FfB were 0.15mg/g
vicenin-2, 0.20mg/g vitexin, 0.30mg/g isovitexin, and 0.25mg/g
6-C-glycoside-diosmetin.
Despite the evidence from our studies, few studies have
examined the effects of a flavonoid fraction on fear memory.
Further, previous data from our group suggest that the FfB may
modulate different neurochemical systems.
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Behavioral, Pharmacological, and
Molecular Analysis
The timelines illustrating the time points of drug administration
and of brain removal are shown in Figures 2A, 3A, 4A and
5A. The effects of treatment with FfB and with agonists
and antagonists specific to 5-HT1ARs, GluN2B-NMDARs, and
GABAARs or antagonists before FfB on the acquisition and
extinction of the suppression of the licking response were
assessed according to the mean SR for each tone, measured
across 10 trials Figures 2B, 3B, 4B and 5B. Every figure
shows the mean SRs for the CS on the first trial and
each three-trial block from the retention test, extinction
training, and extinction retention test sessions. The first trial
is presented independently because it represents the first
presentation of the CS after conditioning, extinction training,
or retrieval of extinction; thus, the results from this trial can
characterize the level of fear of the animal in each situation.
In addition, the results from the first trial can show (i) the
duration of fear memory expression and (ii) the occurrence of
spontaneous recovery. The means (±SEM) for each first trial
FIGURE 2 | (A) Timeline illustrating the time points of drug administration and brain removal. (B) Mean SR of licking behavior in the retention test session (8th day,
n = 20/group), extinction training (9th day, n = 10/group) and the extinction retention test (10th day, n = 10/group). The first point indicates the mean SR for the CS,
learning, Sintocalmy®, Tween®, 0.15mg.Kg−1 FfB, 0.30mg.Kg−1FfB, and 0.65 mg.Kg−1FfB subgroups. The subsequent data points represent the mean of nine
trials in blocks of three trials. The drugs and vehicle were administered orally 30min before the fear conditioning session; the CS and CS-US groups received no
treatment. The data are reported as the means (±SEM). A repeated measures ANOVA was employed for the intra-group comparison of the retention test, extinction
training and extinction retention test (CS presentation) results. This analysis was performed considering two fixed factors (group and trial) and one random factor (rat)
using GraphPad Prism software. he relative Htr1a, Grin2b, Grin2a, Gabra5, and Erk2 mRNA expression levels in the DH after acute treatment with Sintocalmy®,
Tween®, 0.15mg.Kg−1FfB, 0.30mg.Kg−1FfB, or 0.65 mg.Kg−1FfB (n = 3/subgroup) followed by the retention test (C) or the extinction retention test (D). The
CS-US, CS, and naïve subgroups did not receive treatment (n = 3/subgroup). The values are expressed as the means (± SEM). *P < 0.05 and ***P < 0.0001.
###P < 0.0001 according to ANOVA followed by post-hoc Bonferroni tests, when necessary.
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FIGURE 3 | (A) Timeline illustrating the time points of drug administration and brain removal. (B) Mean SR of licking behavior in the test session (8th day,
n = 20/group), extinction training (9th day, n = 10/group) and the extinction retention test (10th day, n = 10/group). The first point indicates the mean SR for the saline,
0.3 mg.Kg−1 (S)-WAY100135, 10mg.Kg−1 buspirone, and 0.3mg.Kg−1 (S)-WAY100135+FfB (0.15mg.Kg−1 FfB, 0.30mg.Kg−1 FfB, or 0.65mg.Kg−1 FfB)
subgroups. The subsequent data points represent the mean of nine trials in blocks of three trials. The drugs and vehicle were administered orally 30min before the
fear conditioning session. The data are reported as the means (±SEM). A repeated measures ANOVA was employed for the intra-group comparison of the retention
test, extinction training and extinction retention test (CS presentation) results. This analysis was performed considering two fixed factors (group and trial) and one
random factor (rat) using GraphPad Prism software. The relative Htr1a, Grin2b, Grin2a, Gabra5, and Erk2 mRNA expression levels in the DH after acute treatment with
0.3mg.Kg−1 (S)-WAY100135, 10 mg.Kg−1 buspirone, 0.3mg.Kg−1 (S)-WAY100135 + (FfB 0.15mg.Kg−1 FfB, 0.30mg.Kg−1 FfB, or 0.65mg.Kg−1 FfB) or saline
(n = 3/subgroup) followed by the retention test (C) orthe extinction retention test (D). The values are expressed as the means (± SEM). *P < 0.05 and ***P < 0.0001.
###P < 0.0001 according to ANOVA followed by post-hoc Bonferroni tests, when necessary.
and block of three trials are presented in Tables S2, S4, S6
and S8.
To investigate the molecular mechanisms involved in
modulating the suppression of the licking response by FfB,
the expression levels of Grin2a, Grin2b, Gabra5, Htr1a, and
Erk2 in the DH were assayed by qRT-PCR. The effects of
FfB, agonists and antagonists specific to the glutamatergic,
serotoninergic and GABAergic systems were evaluated 3 h
after the retention test session (8th day; Figures 2C, 3C, 4C
and 5C) and the extinction retention test session (10th day;
Figures 2D, 3D, 4D and 5D). The mean ± SEM values for the
RE of candidate genes (ddCt) are available in Tables S3, S5,
S7, S9.
Further, we have made statistical comparison between
control groups, which received the vehicle solutions (Saline
and Tween R©). To comparison of SR means during all trial
of presentation of CS we used Paired t-test. No statistically
significant difference was found between-session or intra-session
(P = 0.1450). To comparisons of differential gene expression
from samples of DH, we have used unpaired T-test. Comparisons
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FIGURE 4 | (A) Timeline illustrating the time points of drug administration and brain removal. (B) Mean SR of licking behavior in the test session (8th day,
n = 20/group), extinction training (9th day, n = 10/group) and the extinction retention test (10th day, n = 10/group). The first point indicates the mean SR for the 0.9%
saline, 3.0mg.Kg−1 Ro25-6981, 10mg.Kg−1 NMDA, and Ro25-6981+FfB (0.15 mg.Kg−1 FfB, 0.30mg.Kg−1 FfB, or 0.65mg.Kg−1 FfB) subgroups. The
subsequent data points represent the mean of nine trials in blocks of three trials. The drugs and vehicle were administered orally 30min before the fear conditioning
session. The data are reported as the means (±SEM). A repeated measures ANOVA was employed for the intra-group comparison of the retention test, extinction
training and extinction retention test (CS presentation) results. This analysis was performed considering two fixed factors (group and trial) and one random factor (rat)
using GraphPad Prism software. The relative Htr1a, Grin2b, Grin2a, Gabra5, and Erk2 mRNA expression levels in the DH after acute treatment with 3.0mg.Kg−1
Ro25-6981, 10.0 mg.Kg−1 NMDA, 3.0 mg.Kg−1 Ro25-6981+FfB (0.15mg.Kg−1 FfB, 0.30mg.Kg−1 FfB, or 0.65mg.Kg−1 FfB), or saline (n = 3/subgroup)
followed by the retention test (C) or the extinction retention test (D). The values are expressed as the means (±SEM). *P < 0.05, **P < 0.01 and ***P < 0.0001.
###P < 0.0001 according to ANOVA followed by post-hoc Bonferroni tests, when necessary.
between Saline and Tween R© groups, after retention test (8th
day), were made to each gene evaluated. No significant difference
was observed in the RE levels of Htr1a (P = 0.9737), Grin2b
(P = 0.9691), Gabra5 (P = 0.9592), Grin2a (P = 0.7358), or
Erk2 (P = 0.0962). Comparisons between Saline and Tween R©
groups, after extinction retention test (10th day), were made to
each gene evaluated, similarly to aforementioned, no significant
difference between groups was observed in the RE levels ofHtr1a
(P = 0.5834),Grin2b (P = 0.9208),Gabra5 (P = 0.9982),Grin2a
(P = 0.9628), or Erk2 (P = 0.1469).
Effects of FfB on the Acquisition and Extinction of
Suppression of the Licking Response
The effects of FfB on the acquisition and extinction of
suppression of the licking response are shown in Figure 2B and
Table S2. A Two-way ANOVA revealed a significant group× trial
interaction [F(66, 756) = 2.785, P < 0.0001], a main effect of
group [F(66, 756) = 24.56, P < 0.0001] and a main effect of trial
[F(11, 756) = 17.27, P < 0.0001].
Comparisons of the results for the first trial in the retention
test sessions between groups revealed elevated SR in the
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FIGURE 5 | (A) Timeline illustrating the time points of drug administration and brain removal. (B) Mean SR of licking behavior in the test session (8th day,
n = 20/group), extinction training (9th day, n = 10/group), and the extinction retention test (10th day, n = 10/group). The first point indicates the mean SR of the 0.9%
saline, 0.75mg.Kg−1 picrotoxin, 4mg.Kg−1 diazepam, and 0.75mg.Kg−1 picrotoxin+FfB (0.15mg.Kg−1 FfB, 0.30mg.Kg−1 FfB, or 0.65mg.Kg−1 FfB) subgroups.
The subsequent data points represent the mean of nine trials in blocks of three trials. The drugs and vehicle were administered orally 30min before the fear
conditioning session. The data are reported as the means (±SEM). A repeated measures ANOVA was employed for the intra-group comparison of the retention test,
extinction training and extinction retention test (CS presentation) results. This analysis was performed considering two fixed factors (group and trial) and one random
factor (rat) using GraphPad Prism software. The relative Htr1a, Grin2b, Grin2a, Gabra5, and Erk2 mRNA expression levels in the DH after acute treatment with
0.75mg.Kg−1 picrotoxin, 4mg.Kg−1 diazepam, 0.75mg.Kg−1 picrotoxin+FfB (0.15mg.Kg−1 FfB, 0.30mg.Kg−1 FfB, or 0.65 mg.Kg−1 FfB), or saline
(n = 3/subgroup) followed by the retention test (C) or the extinction retention test (D). The values are expressed as the means (±SEM). *P < 0.05, **P < 0.01 and
***P < 0.0001. ###P < 0.0001 according to ANOVA followed by post-hoc Bonferroni tests, when necessary.
subgroups treated with FfB, CS-US or Tween and reduced SR
in the subgroups treated with Sintocalmy R© or CS (P < 0.0001;
left panel of Figure 2B). The analysis of SR in the first three-
trial block (2nd–4th trials) showed a significant decrease in mean
SR relative to the first trial in the Tween R©, CS-US, and FfB
subgroups (P < 0.0001); these results indicated the acquisition
of extinction of fear memory within the session. An ANOVA
comparing the three-trial blocks revealed no differences within
sessions (P > 0.05). This finding indicated a reliable decrease in
suppression and a reduction of fear after each session.
The middle panel of Figure 2B depicts the data from the
extinction training session conducted 24 h after the retention
test. Treatment with FfB at all doses promoted spontaneous
recovery, as demonstrated by the results for the first trial in each
subgroup, compared to treatment with Tween R© or Sintocalmy R©
or to CS or CS-US alone. However, in subsequent trials, rats
treated with FfB acquired fear extinction within the session
(P < 0.0001). The Tween R© and CS-US subgroups exhibited a
similar SR mean across successive exposures to the CS during the
extinction training session, as observed in the retention test. The
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Sintocalmy R© and CS subgroups showed mean SRs during all CS
presentations that were similar to thosemeasured in the retention
test (P > 0.05). This result indicated no conditioned fear and, as
a consequence, no acquisition of fear extinction.
The right panel of Figure 2B shows the mean SRs in the
extinction retention session conducted 24 h after extinction
training. The subgroups treated with FfB exhibited spontaneous
recovery in the first trial, similar to the behavior observed during
the extinction training session. However, all subgroups exhibited
similar behavior by the end of the session. Notably, for the
first trials, the mean SRs for each subgroup treated with FfB
were significantly different from those for the Tween R© and CS
subgroups (P < 0.0001). Comparisons between the first trial
and the first three-trial block (2–4) showed reduced suppression
of the licking response in the Tween R©, CS-US and all FfB
subgroups (P < 0.0001). An ANOVA comparing the results
for the three-trial blocks within the session demonstrated no
significant differences in the mean SR between the subgroups
(P > 0.05). In addition, no significant differences in the mean SR
were observed in the CS subgroup across all sessions (P > 0.05).
In summary, our data show for the first time that FfB
does not impair the conditioned fear. However, rats treated
with FfB showed spontaneous recovery of fear conditioning,
as observed in the extinction training and extinction retention
test sessions, although FfB did not prevent the acquisition
within-session extinction. Furthermore, acute treatment with
Sintocalmy R©, a standardized extract containing 7% of the total
flavonoids expressed in vitexin, impaired the conditioned fear
and, consequently, resulted in no acquisition of the extinction of
fear conditioning.
FfB Treatment Modulates the Spontaneous Recovery
of Fear Memory via Htr1a and Erk2 Expression Within
the DH
FfB treatment at three different doses resulted in the
overexpression of Htr1a [F(7, 16) = 173.0, P < 0.0001],
Grin2a [F(7, 16) = 165.2, P < 0.0001], Gabra5 [F(7, 16) = 40.82,
P < 0.0001], and Erk2 [F(7, 16) = 155.5, P < 0.0001] in the
DH after the retention test session (8th day) compared with
the control treatments (Tween R©, Sintocalmy R©, CS-US, CS,
and naïve; Figure 2C). The Htr1a, Grin2b, Grin2a, Gabra5, and
Erk2 expression levels were increased in the control subgroups
(Tween R© and CS-US subgroups) compared with the CS and
naïve subgroups (P < 0.0001). No difference was observed
in Grin2b [F(7, 16) = 13.97] expression after treatment with
FfB compared to the treatment with FfB and CS-US groups
(P > 0.05; Figure 2C and Table S3), and Grin2a expression
decreased after treatment with Sintocalmy R©(P < 0.0001).
In the extinction retention test, Htr1a [F(7, 16) = 96.39] and
Erk2 [F(7, 16) = 388.9; P < 0.0001] expression was significantly
increased after FfB treatment in the DH compared with all
other treatments (P < 0.0001; Figure 2D and Table S3). No
significant difference in the RE levels ofGrin2b [F(7, 16) = 12.20],
Gabra5 [F(7, 16) = 16.11], or Grin2a [F(7, 16) = 181.6] was
observed in the FfB-treated subgroups compared to the CS-US
or Tween R© subgroups (P > 0.05), although these expression
levels were increased compared to the CS and naïve subgroups
(P < 0.05). Furthermore, Grin2a expression was reduced
following the extinction retention test due to treatment with
Sintocalmy R© compared with all other treatments (Tween R© and
CS-US treatments; P < 0.0001).
In summary, the acquisition and extinction of the suppression
of the licking response modulated Htr1a, Grin2b, Grin2a,
Gabra5, and Erk2 expression, and FfB treatment altered Htr1a,
Grin2a, Gabra5, and Erk2 expression after the retention test.
Furthermore, the spontaneous recovery of fear memory appears
to correlate with the overexpression of Htr1a and Grin2a in the
DH.
Effects of FfB on Fear Memory After Blocking
5-HT1ARs
Figure 3B illustrates the specific effects of blocking 5-
HT1ARs before FfB treatment, which was administered
before conditioning, on the results for the retention test,
extinction training, and the extinction retention test. A Two-
way ANOVA revealed a significant trial × group interaction
[F(55, 648) = 1.365, P = 0.0453], a main effect of group
[F(5, 648) = 2.792, P = 0.0166] and a main effect of trial
[F(11, 648) = 9.116, P < 0.0001]. Similar mean SRs were observed
between the Tween and saline groups across sessions (P > 0.05).
Therefore, saline was used to compare the effects of antagonists
and agonists together with FfB.
The left panel of Figure 3B shows the mean SRs in the
CS, negative control (saline), positive control (0.30mg.Kg−1
(S)-WAY100135 and 10.0mg.Kg−1 buspirone), and treated
subgroups [0.30 mg.Kg−1 (S)-WAY+FfB (0.15mg.Kg−1;
0.30mg.Kg−1; or 0.65mg.Kg−1FfB)] for the retention test
session. The analysis of mean SR for the first trial showed that
treatment with (S)-WAY100135 or (S)-WAY100135 before FfB
resulted in reduced suppression of the licking response compared
with saline (P < 0.0001) and buspirone treatment (P < 0.0001).
Analysis of the SR for the first three-trial block (2nd–4th trials)
showed significant differences in the mean SRs compared to the
first trial in the saline and buspirone subgroups (P < 0.0001).
This result demonstrates acquisition within-session extinction to
these subgroups. Alternatively no such differences were observed
in the (S)-WAY100135 or (S)-WAY+FfB subgroups (P > 0.05).
An ANOVA comparing the first three-trial block (2–4) with the
subsequent three-trial blocks (5–7 and 8–10) demonstrated no
significant differences in mean SR on the extinction retention
session between the subgroups (P > 0.05; see Table S4).
The data from the extinction training tests are shown in the
middle panel of Figure 3B. Comparisons between groups showed
that the groups treated with (S)-WAY+FfB, at all doses, did not
demonstrate a difference in the mean SR (P > 0.05). Analysis
of the mean SR during the first three-trial block (2–4) showed
that rats treated with (S)-WAY+FfB, saline, buspirone or (S)-
WAY100135 exhibited a similar mean SR to that in the first trial
(P > 0.05). Moreover, similar mean SRs were observed with in
all groups for the subsequent three-trial blocks (5–7 and 8–10;
P > 0.05; see also Table S4).
The data from the extinction retention tests are shown in
the right panel of Figure 3B. The analysis of the SR showed
that the subgroups treated with (S)-WAY100135+FfB did not
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exhibit spontaneous recovery. Furthermore, the analysis of the
mean SR showed no significant difference between the first
three-trial block (2nd–4th trial) and the first trial among the
(S)-WAY100135+FfB subgroups at all doses (P < 0.0001).
Therefore, no significant differences in mean SRs were found
among the subgroups between the first three-trial block (2–4) and
the subsequent three-trial blocks (5–7 and 8–10; P > 0.05; see
Table S4).
A Two-way ANOVA comparison between groups treated with
FfB vs. (S)-WAY100135+FfB revealed a significant groups× trial
interaction [F(55, 495) = 2.018, P < 0.0001] and main effects of
trial [F(11, 99) = 21.25, P < 0.0001] and groups [F(5, 45) = 21.41,
P < 0.0001]. Treatment with (S)-WAY100135+ 030mg.Kg−1
FfB and (S)-WAY100135+ 065mg.Kg−1 FfB, resulted in reduced
of licking response compared with FfB group in the first
trial during extinction training. No significant difference was
observed among subsequent three-trial blocks. Furthermore, the
analysis of the mean SR showed significant difference between
(S)-WAY100135 + 0.65mg.Kg−1 FfB and 0.65mg.Kg−1 FfB to
the first trial during extinction retention test (P < 0.0001). No
significant difference was observed among subsequent three-trial
blocks.
In summary, our data demonstrate that (S)-WAY+FfB, at all
doses, reduces the suppression of the licking response compared
with the control treatment, as demonstrated by the results from
the retention test. These data suggest for the first time that
the spontaneous recovery observed in the FfB subgroups is
modulated by 5-HT1ARs.
(S)-WAY100135 Treatment Prevents the
Overexpression of Htr1a and Erk2 Within the DH
Caused by FfB
We used treatment with (S)-WAY100135 prior to FfB
administration to assess the role of the 5-HT1AR in the
acquisition and extinction of fear memory. In addition, the roles
of NMDARs, GABAARS,and ERK2 were evaluated.
Figure 3C shows the levels of Htr1a, Gabra5, Grin2a,
Grin2b, and Erk2 expression in the DH after the retention
test session (8th day). Consistent with the results of Htr1a and
Erk2 expression after FfB administration, treatment with (S)-
WAY100135+FfB, at all doses, resulted in the downregulation
of Htr1a expression [F(5, 12) = 449.9, P < 0.0001]. Treatment
with (S)-WAY100135+FfB resulted in the downregulation of
Htr1a expression when compared with saline and buspirone
treatment [F(5, 12) = 40.05, P < 0.0001]. Although Erk2
expression was similar across all groups [F(5, 12) = 3.071,
P = 0.0516]. A ANOVA comparison between the groups
treated with (S)-WAY100135+FfB vs. FfB revealed that the
overexpression of Erk2 observed after FfB treatment was reversed
by (S)-WAY100135 pretreatment, at all doses [F(5, 12) = 57.79,
P < 0.0001]. Furthermore, (S)-WAY100135+FfB induced
the downregulation of Grin2a [F(5, 12) = 124.8] and Grin2b
[F(5, 12) = 8.794;P = 0.001] expression compared with saline
and buspirone (P < 0.0001). Moreover, (S)-WAY100135
treatment decreased the expression of Grin2a, but not Grin2b,
and buspirone treatment reduced Grin2b expression compared
with saline treatment (P < 0.0001). No significant changes in
Gabra5 expression were observed [F(5, 12) = 2.505, P = 0.0894].
These statistics are shown in Table S5.
Figure 3D shows Htr1a, Gabra5, Grin2a, Grin2b, and Erk2
expression in the DH after the extinction retention test (10th
day). These data show that treatment with (S)-WAY100135
before FfB administration, at three different doses, resulted in
the overexpression of Grin2a [F(5, 12) = 278.4, P < 0.0001]
compared with the control treatments [saline, buspirone, and (S)-
WAY100135] and in the downregulation of Gabra5 compared to
treatment with 0.15mg.Kg−1 FfB [F(5, 12) = 4.338, P = 0.0174].
Additionally, treatment with (S)-WAY100135+FfB resulted in
the downregulation of Htr1a [F(5, 12) = 31.18, P < 0.0001],
Erk2 [F(5, 12) = 119.9, P < 0.0001] and Gabra5 expression
[F(5, 12) = 20.48, P < 0.0001] and overexpression of Grin2a in
the DH [F(5, 12) = 82.00, P < 0.0001]. Furthermore, treatment
with buspirone resulted in the upregulation of Htr1a expression
[F(5, 12) = 72.92; P < 0.001] compared with all other treatments.
Nevertheless, no significant differences were observed in the RE
of Grin2b [F(5, 12) = 3.039, P = 0.0010] or Erk2 [F(5, 12) =
2.94, P = 0.0580]. Treatment with (S)-WAY100135 prior to FfB
administration, at all three doses, prevented the upregulation of
Htr1a expression observed after FfB treatment (Figure 2D; see
also Table S5).
In summary, our data show that treatment with (S)-
WAY100135 prior to FfB administration decreasesHtr1a,Grin2b,
and Grin2a expression in the DH after the retention test and
prevents the increase in Htr1a and Erk2 expression after the
extinction retention test in relation to observed after treatment
with FfB alone. Conversely, Grin2a expression in the DH
was increased after (S)-WAY100135+FfB treatment after the
extinction retention test compared with FfB treatment.
Effects of FfB on Fear Memory After Blocking
GluN2B-NMDARs
Figure 4B shows the effects of specifically blocking GluN2B-
NMDARs with Ro25-6981 before FfB treatment, which was
administered before conditioning, on the results from the
retention test, extinction training and the extinction retention
test. A Two-way ANOVA revealed a significant trial × group
interaction [F(55, 648) = 2.170, P < 0.0001], a main effect of
group [F(5, 648) = 3.356, P < 0.0001] and a main effect of trial
[F(11, 648) = 11.57, P < 0.0001].
The left panel of Figure 4B shows the mean SRs for
the retention test session. Comparisons of the mean SR on
the first trial revealed a difference between the Ro25-6981-
treated subgroup and all other subgroups (P > 0.0001);
this result indicated that blockade of GluN2B impaired the
acquisition of fear memory. However, treatment with Ro25-
6981 before FfB administration did not affect fear memory.
FfB treatment reversed the learning impairment observed in
the subgroup treated with Ro25-6981 alone. Analysis of the SR
for the first three-trial block (2nd–4th trials) showed significant
differences in mean SR for the saline, NMDA, Ro25-6981,
andRo25-6981+FfB groups (0.15mg.Kg−1;0.30mg.Kg−1; or 0.65
mg.Kg−1FfB) compared with the first trial (P < 0.0001).
Furthermore, an ANOVA comparing the subsequent three-trial
blocks (5–7 and 8–10) with the first three-trial block of the test
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revealed no differences (P > 0.05). The Ro25-6981 subgroup
showed similar SR values across all trials of CS presentation
(statistics shown in Table S6).
However, comparisons of the first trial of the extinction
training test between the subgroups showed that the subgroups
treated with Ro25-6981+FfB, at all doses, did not demonstrate
differences in mean SR compared with the saline and NMDA
subgroups (P > 0.05) or the Ro25-6981 alone subgroup, which
showed no acquisition of conditioned fear (middle panel of
Figure 4B). Analysis of the SR for the first three-trial block
(2nd–4th trials) compared with the first trial showed no significant
differences in the mean SR for the subgroups treated with
saline, NMDA, Ro25-6981, or Ro25-6981+FfB (P > 0.05).
Nevertheless, no significant difference in SR was found within
the groups for the first three-trial block (2–4) compared with the
subsequent three-trial blocks (5–7 and 8–10; P > 0.05; see also
Table S6).
The subgroups treated with Ro25-6981+FfB, at all doses,
exhibited higher mean SRs for the first trial than the saline
subgroup on the extinction retention test (P > 0.05; right
panel of Figure 4B) and remained similar throughout the
trials of the extinction training test. Comparisons between the
first trial and the first three-trial block (2–4) showed reduced
suppression of the licking response for all groups treated with
Ro25-6981+FfB (P < 0.05). An ANOVA comparing the three-
trial blocks demonstrated no significant differences in the mean
SRs throughout the extinction retention session (P > 0.05;
Table S6).
A Two-way ANOVA comparison between groups treated
with FfB vs. Ro 25-6981+FfB revealed a significant groups ×
trial interaction [F(55, 495) = 2.094, P < 0.0001] and main
effects of trial [F(11, 99) = 31.20, P < 0.0001] and groups
[F(5, 45) = 2.873, P = 0.0247). Analysis of the mean SR showed
significant difference between Ro 25-6981 + 0.65mg.Kg−1 FfB
vs. 0.65mg.Kg−1 FfB to the first trial during extinction training
(P < 0.0001). No significant difference was observed among
subsequent three-trial blocks (P > 0.05). Furthermore, similar
means SR were found to groups treated with Ro 25-6981+FfB
to the first trial during extinction retention test. No significant
difference was observed among subsequent three-trial blocks
(P > 0.05).
In summary, our data show for the first time that
treatment with Ro25-6981, an antagonist of the GluN2B-
NMDAR, impairs the acquisition of suppression of the licking
response. Conversely, treatment with after FfB after Ro25-6981
administration, at all doses, reverses the learning impairment
associated with the GluN2B-NMDAR antagonist. In this sense,
GluN2B is involved in the acquisition of suppression of the
licking response, but the disruptive effects of Ro25-6981 appear
to be offset by treatment with FfB. Additionally, we showed
that the spontaneous recovery observed in the FfB subgroups
may be modulated by GluN2B because rats treated with
Ro25-6981 before FfB administration seems to decrease the
spontaneous recovery observed during the extinction training
sessions compared with the rats treated with FfB alone (see
Figure 2B).
Ro25-6981 Treatment does not Prevent the
Overexpression of Grin2a and Erk2 Caused by FfB,
Although it Reduces Htr1a Expression
We used treatment with Ro25-6981 prior to FfB to evaluate the
roles of NMDARs, 5-HT1ARS, GABAARS, and ERK2. Figure 4C
shows the Htr1a, Grin2a, Grin2b, Gabra5, and Erk2 expression
levels in the DH after the retention test (8th day). Treatment with
Ro25-6981 before FfB treatment, at all three doses, resulted in
the overexpression of Grin2a [F(5, 12) = 107.1, P < 0.0001]
and Erk2 [F(5, 12) = 90.89, P < 0.0001] and the decreased
expression of Htr1a [F(5, 12) = 32.67, P < 0.0001] and Gabra5
[F(5, 12) = 12.44, P = 0.0002] compared with the control
treatment. No change inGrin2bwas observed after Ro25-6981 or
Ro25-6981+FfB treatment [F(5, 12) = 20.18]. A ANOVA analysis
revealed that treatment with Ro25-6981 before FfB, resulted in
the overexpression of Grin2a [F(5, 12) = 134.8, P < 0.0001] and
Erk2 [F(5, 12) = 47.98, P < 0.0001] and the decreased expression
of Htr1a [F(5, 12) = 361.7, P < 0.0001] and Gabra5 [F(5, 12) =
32.57, P < 0.0001] in relation to groups treated with FfB alone.
Additionally, NMDA treatment resulted in the overexpression of
Grin2b compared with all other treatments (P < 0.0001) and in
the overexpression of Erk2 compared with saline or Ro25-6981
treatment (P < 0.001; see Table S7).
Figure 4D shows that treatment with Ro25-6981+FfB
increased the Grin2a [F(5, 12) = 14.47, P = 0.0001], Erk2
[F(5, 12) = 44.78, P < 0.0001], Htr1a [F(5, 12) = 158.6,
P < 0.0001], and Grin2b [F(5, 12) = 5.37, P = 0.008]
expression levels in the DH after the extinction retention test
(10th day) compared with saline treatment. No significant
differences in Gabra5 expression were observed between the
subgroups treated with Ro25-6981+FfB and the saline subgroup
[F(5, 12) = 1.169, P = 0.3790]. Furthermore, comparison among
groups treated with Ro25-6981 before FfB treatment resulted in
the overexpression of Grin2a [F(5, 12) = 32.68, P < 0.0001] and
Erk2 [F(5, 12) = 34.58, P < 0.0001] and Htr1a [F(5, 12) = 299.0,
P < 0.0001]. Further, significant difference tog Grin2b was
seeing to groups treated with Ro25-6981 before 0.65mg.Kg−1
FfB in relation to 0.65mg.Kg−1 FfB group [F(5, 12) = 4.727,
P = 0.0128].
In summary, treatment with Ro25-6981 reduced the
expression of Gabra5, Erk2, and Ht1ra in the DH after the
retention test, although treatment with FfB reduced the effects
of Ro25-6981 on Gabra5 and Htr1a expression and increased
Grin2a and Erk2 expression. Conversely, treatment with Ro25-
6981+FfB increased Htr1a expression after the extinction
retention test. Furthermore, treatment with FfB after Ro25-6981
administration increased the Htr1a, Grin2b, Grin2a, and Erk2
expression levels in the DH after the extinction retention test
(see Table S7).
Effects of FfB on Fear Memory After Blocking
GABAARs
The effects of specifically blocking GABAARs prior to FfB
treatment before conditioning on the results of the retention test,
extinction training, and the extinction retention test are shown
in Figure 5B. A Two-way ANOVA revealed a significant trial ×
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group interaction [F(55, 648) = 2.695, P < 0.0001], a main effect
of group [F(5, 648) = 6.416, P < 0.0001] and a main effect of trial
[F(11, 648) = 11.77, P < 0.0001].
Analysis of the mean SRs for the first trial of the retention
test showed that treatment with picrotoxin, an antagonist of
GABAARs, or picrotoxin+FfB did not prevent the acquisition of
conditioned fear. These subgroups showed a similar mean SR to
the saline subgroup (P > 0.05). Conversely, animals treated with
diazepam exhibited reduced suppression of the licking response
compared with the animals treated with saline, picrotoxin or
picrotoxin+FfB (P < 0.001).
Analysis of the SR for the first three-trial block (2nd–4th
trials) compared with the first trial showed significant differences
in the mean SR for the subgroups treated with saline,
picrotoxin, or picrotoxin+FfB (0.15mg.Kg−1, 0.30mg.Kg−1, or
0.65mg.Kg−1FfB; P < 0.0001). An ANOVA comparing the first
three-trial block (2–4) of extinction with the other three-trial
blocks (5–7 and 8–10) demonstrated no significant differences in
the mean SR between the subgroups (P > 0.05; see Table S8).
The data from the extinction training session are shown in
the middle panel of Figure 5B. Comparisons between the groups
showed that the subgroups treated with picrotoxin+FfB, at all
doses, demonstrated differences in mean SRs in the first trial
compared to the saline, picrotoxin and diazepam subgroups (P <
0.0001). In addition, rats treated with picrotoxin+FfB showed
spontaneous recovery similar to that observed in rats treated
with FfB alone (see Figure 2B). Furthermore, no differences
in SR on the first trial were observed between the saline and
picrotoxin subgroups (P > 0.05). Analysis of the mean SR during
the first three-trial block (2–4) showed that rats treated with
picrotoxin+FfB at all doses demonstrated reduced suppression
of the licking response compared with the mean SR for the
first trial (P < 0.0001). The saline and picrotoxin subgroups
exhibited a similar mean SR across successive exposures to the
CS during extinction training. Similar mean SRs were observed
for all groups across the subsequent three-trial blocks (5–7 and
8–10; P > 0.05; see Table S8).
Similar to the previous sessions, on the extinction retention
test, rats treated with picrotoxin+FfB, at all doses, showed
spontaneous recovery on the first trial, as demonstrated by the
higher SR means in the picrotoxin+FfB subgroups (P > 0.001;
Figure 5B, right panel). A reduced mean SR was observed in the
picrotoxin+FfB subgroups on the first three-trial block compared
to the first trial (P < 0.0001). No significant difference in the SR
was found within the groups for the first three-trial block (2–4)
compared with the subsequent three-trial blocks (5–7 and 8–10;
P > 0.05; see also Table S8).
A Two-way ANOVA comparison between groups treated with
FfB vs. Picrotoxin+FfB revealed a significant groups × trial
interaction [F(55, 495) = 1.091, P = 0.3116] and main effects of
trial [F(11, 99) = 45.11, P < 0.0001] and groups [F(5, 45) = 5.375,
P = 0.0006]. Analysis of the mean SR showed no significant
difference between groups treated with FfB vs. Picrotoxin+FfB,
at all doses, to the first trial during retention test (P > 0.05),
extinction training (P > 0.05) and extinction test sessions
(P > 0.05). Significantly difference were observed among groups
treated with FfB, at a dose 0.15mg.Kg−1 and 0.65mg.Kg−1FfB
(P < 0.05). Furthermore, analysis of SR means for the first trial
showed significant difference among rats treated with different
doses of FfB groups during extinction training and extinction
retention test (P < 0.001). No significant difference was observed
among subsequent three-trial blocks (P > 0.05).
In summary, our data demonstrated that each group
treated with picrotoxin prior to FfB administration acquired
fear memory. Conversely, diazepam treatment impaired the
acquisition of fear memory. Furthermore, we showed that
treatment with picrotoxin+FfB resulted in spontaneous recovery
in the first trial of extinction training and the extinction retention
test, although the suppression gradually decreased over the trials.
Therefore, rats treated with FfB showed within-session extinction
of fear memory. These data suggest that spontaneous recovery is
not modulated by GABAARs.
Picrotoxin Prevents the Overexpression of Gabra5
and Grin2a Caused by FfB
Treatment with picrotoxin prior to FfB treatment, at a dose of
0.15 or 0.65mg.Kg−1 FfB, did not prevent the increase in the
expression of Htr1a [F(5, 12) = 28.02, P < 0.0001] or Erk2
[F(5, 12) = 84.48, P < 0.0001] in the DH after the retention
test compared with saline, picrotoxin, or diazepam treatment
(Figure 5C), as observed in the subgroups treated with FfB alone
(Figure 2C). A ANOVA analysis revealed that treatment with
picrotoxin before FfB, resulted in the downexpression of Htr1a
[F(5, 12) = 128.7 P < 0.0001], Grin2b [F(5, 12) = 15.22, P <
0.0001] and Erk2 [F(5, 12) = 22.81, P < 0.0001], at all doses, and
Gabra5 [F(5, 12) = 28.02, P < 0.0001] andGrin2a [F(5, 12) = 8515,
P < 0.00002], at a higher doses in relation to groups treated with
FfB alone. Additionally, picrotoxin+FfB treatment did reduce
Grin2b expression [F(5, 12) = 14.42, P < 0.0001], but no change
was observed in the expression of Grin2a [F(5, 12) = 12.24, P =
0.0001] or Gabra5 [F(5, 12) = 7.580, P = 0.0020]. Furthermore,
picrotoxin increased Gabra5, and Erk2 expression in the DH
(P < 0.0001). Conversely, diazepam treatment decreased Htr1a,
Grin2a, Erk2, and Grin2b expression in the DH (see Table S9).
The data shown in Figure 5D demonstrate the upregulation
of Erk2 [F(5, 12) = 90.76, P < 0.0001] and Grin2a [F(5, 12) =
67.51] expression in the DH after the extinction retention session
for the subgroups treated with picrotoxin+FfB compared to
those treated with saline, picrotoxin or diazepam (P > 0.0001).
Upregulated Htr1a [F(5, 12) = 23.98, P < 0.0001] and Erk2
[F(5, 12) = 26.24, P < 0.0001] expression was observed
in the picrotoxin+FfB in relation to FfB group. Similarly,
upregulated Htr1a [F(5, 12) = 10.75] expression was observed
in the picrotoxin+FfB compared with the saline and diazepam
subgroups (P < 0.0001). Moreover, we showed that picrotoxin
resulted in the overexpression of Htr1a, Grin2b [F(5, 12) = 31.61,
P < 0.0001], and Gabra5 [F(5, 12) = 12.13, P = 0.0020]
compared with saline. Downregulated Grin2b [F(5, 12) = 22.08,
P < 0.0001], Grin2a [F(5, 12) = 22.04, P < 0.0001] and Gabra5
[F(5, 12) = 14.46, P < 0.0001] expression was observed in the
picrotoxin+FfB in relation to FfB group. Furthermore, diazepam
increased Htr1a expression and decreased Grin2a and Gabra5
expression (P < 0.0001; see Table S9).
In summary, treatment with picrotoxin before FfB
administration, at all doses, increased Htr1a and Erk2 expression
in the DH after the acquisition and extinction of fear memory
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and reduced Grin2b expression and prevented the increase
in Grin2a and Gabra5 expression after the retention test.
Furthermore, this treatment decreased Grin2b and Gabra5
expression after the extinction retention test.
DISCUSSION
The major findings of our study are as follows. (i) Rats treated
with FfB acquired suppression of the licking response, and FfB
upregulated the expression of Htr1a, Grin2a, Gabra5, and Erk2
in the DH after the acquisition of conditioned fear, compared to
rats exposed to the CS alone, naïve rats and Sintocalmy R©-treated
rats. (ii) Rats treated with FfB, at all doses, showed spontaneous
recovery when subjected to the extinction training and extinction
retention test sessions; these observations were correlated with
Htr1a and Erk2 overexpression in the DH. (iii) These findings
were confirmed by data from treatment with (S)-WAY100135,
which reduced the lick SR and inhibit spontaneous recovery.
Further, data from DH samples obtained from rats treated with
(S)-WAY100135 prior to FfB resulted in the downregulation of
Htr1a expression and no modulation of Erk2 expression after
the retention test and the extinction retention test. (iv) Our data
are in line with previous findings concerning the requirement
of GluN2B for fear memory formation (Sotres-Bayon et al.,
2007, 2009). In particular, we present evidence that treatment
with Ro25-6981 disrupts the acquisition of suppression of the
licking response. Nevertheless, treatment with FfB after Ro25-
6981 reversed the dose-dependent deficit in the acquisition of
fear memory caused by Ro25-6981, which was associated with
upregulation of Grin2a and Erk2 expression and downregulation
of Htr1a and Gabra5 expression in the DH after the retention
test. The occurrence of spontaneous recovery to group treated
with Ro25-6981 before FfB during extinction retention test
seems to be associated with increase of Grin2b, Grin2a, and
Erk2 expression. (v) Treatment with picrotoxin prior to FfB
administration no inhibits the spontaneous recovery of fear. This
observation was correlated with overexpression of Htr1a and
Erk2 and no modulation of Gabra5 expression in the DH. This
result suggested that spontaneous fear recovery is not modulated
by inactivation of GABAARs; however, the data concerning
Gabra5 expression in the DH indicated that FfB modulated the
expression of the α5-subunit, which is particularly important for
mediating the process of memory formation in the hippocampus
(Bannerman et al., 2004; Rudolph and Möhler, 2006; Atack,
2011). Additionally, treatment with diazepam and Sintocalmy R©
disrupt the acquisition of fear memory, in which was associated
with downregulation of Grin2a expression in the DH. Several
pharmacological studies have indicated that the administration
of diazepam before training impairs LTM, as evaluated in a
behavioral model such as IA (Izquierdo and Ferreira, 1989),
contextual fear conditioning (Harris and Westbrook, 1998),
or conditioned suppression (Oliveira et al., 2009). Consistent
with this evidence, our results show that acute treatment with
4.0 mg.Kg−1 diazepam impaired fear memory acquisition and
highlight the role of GABAAR in this process. Together with
previous data, our current data further support the concept that
flavonoid fractions do not prevent fear memory extinction within
a session (de Oliveira et al., 2014). In addition, these data suggest
an important role of the DH in mediating the acquisition and
extinction of conditioned suppression of the lick response.
The roles of the hippocampus in the acquisition,
consolidation, and retrieval of fear memory (Kim and Fanselow,
1992; Cammarota et al., 2008) and in fear extinction have been
extensively studied in different rodent paradigms (Izquierdo,
1997; Ji and Maren, 2008). Further, the involvement of a
circuit including the hippocampus, the pre-frontal cortex and
the amygdala in these processes has long been established
(Vinogradova, 2001; Fanselow and Dong, 2010). However, the
present data suggest an important role of the hippocampus
in conditioned suppression, whereas hippocampal plasticity
may represent another function of the hippocampus in
addition to contextual fear memory modulation and executive
and integrative functions (McNaughton and Gray, 2000;
Anagnostaras et al., 2001; Vinogradova, 2001; Sanders et al.,
2003). Further, many theories have attempted to explain both
the neurochemical processes that occur during the acquisition
and extinction of fear memory and in the mechanism by which
new drug, which are designed to enhance the consolidation or
facilitate the extinction of fear memories, might modulate these
neurochemical systems (Ji and Maren, 2007; Dalton et al., 2008).
However, much less is known about drugs that modulate the
brain substrates of extinction, conditioned inhibition, and other
inhibitory processes involved in the suppression of a motivated
response or the basis of spontaneous recovery. In addition,
very few studies have shown the effects of drug treatment prior
to conditioning training on fear extinction or spontaneous
recovery, i.e., the relationship between the strength of fear
memory acquisition and spontaneous recovery. In contrast, the
majority of the existing data show the effects of pre-extinction
treatment on spontaneous recovery.
Our data suggest that the role of the hippocampus in the
acquisition and extinction of lick suppression is dependent
on the interaction between glutamatergic, serotoninergic and
GABAergic neurotransmission via the activation or inactivation
of specificNMDARs, GABAARs, and 5-HT1ARs, as demonstrated
by the results frompharmacologicalmanipulation anddifferential
gene expression of Grin2a, Grin2b, Gabra5, Htr1a, and Erk2.
The reappearance of a conditioned response after acquisition and
training for extinction of fearmemory, as shown in our subgroups
treated with FfB, has been previously described (Bouton, 1993;
Rescorla, 2004; Leung and Westbrook, 2008; Quirk and Mueller,
2008). Specifically, it is thought that the persistence of a fear
response after extinction training is associated with anxiety-
related disorders (Davis et al., 2006). However, we showed that
FfB enabled the acquisition of extinction within a session despite
the occurrence of spontaneous recovery. Although these findings
may seem paradoxical, our current findings raise the hypothesis
that the original memory was somewhat enhanced, i.e., better
preserved; therefore, the flavones from Erythrina falcata may be
studied as a novel pharmacotherapy for the treatment of cognitive
impairment. Furthermore, we believe that the reappearance of
the original memory (spontaneous recovery) observed after FfB
treatment is associated with the expression of Htr1a, Erk2, and
Grin2a in the DH.
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5HT1ARs as a Potential Target for the
Effects of FfB on Spontaneous Recovery
Drugs that modulate the serotoninergic system are important for
cognitive and emotional functions, and 5-HT1ARs are involved
in this process. The heteromeric 5-HT1AR is highly expressed in
the hippocampus (Barnes and Sharp, 1999), where it modulates
GABA- and glutamate-mediated activities (Jacobs and Azmitia,
1992; Barnes and Sharp, 1999; Meneses and Perez-Garcia, 2007).
Activation of post-synaptic 5-HT1ARs (heteroreceptors) in the
hippocampus is a central component of conflict resolution and
anti-anxiety effects. Alternatively, reduced 5-HT1AR expression
results in a deficit in hippocampal-dependent memory (Bert
et al., 2005, 2006; Altieri et al., 2013). However, the effect of the
activation of 5-HT1AR on the modulation of Erk2 expression
remains controversial and may depend on neuronal origin and
maturation states. Treatment with a 5-HT1AR agonist increased
ERK phosphorylation and activity in the hippocampal neuron-
derived cell line HN2-5 and in hippocampal slices cultured from
postnatal day-15 animals (Adayev et al., 1999). In addition to
these effects, the activation of 5-HT1ARs alters the dynamics of
other neurotransmission systems.
The serotonergic regulation of NMDAR function in the DH
was described in pyramidal neurons in the prefrontal cortex
(Yuen et al., 2005). Additionally, the activation of 5-HT1ARs
resulted in disruption of the transport of GluN2B subunit-
containing vesicles in dendrites, and this transport is regulated
by the CaMKII and ERK signaling pathways (Yuen et al.,
2005). However, further investigations of the adaptive changes in
receptor functions and their specific localization are needed to
elucidate the precise role of flavonoids.
Intra-hippocampal treatment with (S)-WAY100135 alone
did not affect the punished response in rats (Przegalinski et al.,
1995). Therefore, our data suggest that treatment with (S)-
WAY100135 reduced lick suppression and that treatment with
FfB was unable to reverse this effect. Moreover, the treatment
with (S)-WAY100135 modulated Grin2a and Grin2b expression.
In this sense, heteromeric 5-HT1ARs in the DH appear to be
related to the acquisition of conditioned fear in addition to
anti-conflict functions because rats treated with (S)-WAY100135
before FfB administration did not show spontaneous
recovery.
The reduced Grin2a, Grin2b, and Htr1a expression in
the DH in groups treated with (S)-WAY100135 or (S)-
WAY+FfB may underlie the reduced lick suppression and lack
of spontaneous recovery. This result suggests an interaction
between neurochemical systems. Therefore, the 5-HT1AR
represents an additional potential target for the regulation of
emotion and cognition in the DH.
Activation of the GluN2B-NMDARs is
Required for Acquisition of Conditioned
Suppression and Their Inactivation Before
FfB Treatments Modulates the
Spontaneous Recovery
Since the discovery of the involvement of NMDARs in long-
term potentiation (LTP) at CA1 synapses in the hippocampus,
it has become evident that NMDARs are critical for a variety
of cognitive processes, such as the acquisition and extinction of
fear conditioning (Morris et al., 1986; Bliss and Collingridge,
1993). GluN2A and GluN2B are the predominant subunits of
NMDARs. Furthermore, both of these subunits are expressed in
the adult brain, predominantly in forebrain regions such as the
amygdala, the prefrontal cortex, and the hippocampus, which
are involved in the signaling pathways required for aversive
memory formation (Schenberg et al., 2006; Mathur et al., 2009;
Sotres-Bayon et al., 2009; Morris, 2013).
The hippocampal functions of NMDARs, particularly the
GluN2B and GluN2A subunits, in fear memory have been
reported (Zhang et al., 2008; Brigman et al., 2010). Several works
have suggested that the NMDAR subunit composition could
be responsible for the induction of the two forms of plasticity:
LTP and long-term depression (LTD) (Shipton and Paulsen,
2014). The contribution of each subunit to ERK2 activation
appears to be related to the localization and population of these
receptors as well as the behavioral paradigm evaluated (Traynelis
et al., 2010). NMDARs either produce weak ERK2 activation or
do not activate ERK2 (Gao et al., 2010). Myung et al. (2005)
showed that the GluN2B-NMDAR is coupled to the inhibition,
rather than the activation, of ERK1/2. Furthermore, differences
between behavioral data and gene expression data may explain
the different effects of the GluN2B-NMDAR on downstream
pathways according to regional localization. Our data showed
that Ro25-6981 downregulated the expression of Erk2 in the DH,
which resulted in the impairment of conditioned suppression.
Alternatively, pharmacological activation of NMDARs increased
Grin2b and Erk2 expression but did not affect Grin2a
expression in the DH after the acquisition of conditioned
suppression. Furthermore, treatment with FfB after Ro25-6951
administration increased Grin2a and Erk2 expression in the
DH. Thus, Erk2 activity is closely related to the acquisition of
conditioned suppression, as well as extinction and spontaneous
recovery.
The increase in Erk2 expression, in response to the acquisition
of fear memory or to NMDAR stimulation, has been consistently
related to memory-dependent plasticity in the hippocampus
(Atkins et al., 1998; Cammarota et al., 2000). The first evidence
for the involvement ofMAPK in LTP and fearmemory originated
from studies by English and Sweatt (1996) and Atkins et al.
(1998), which showed that ERK2 is required for the formation
of LTM in a fear conditioning paradigm in the hippocampus.
The levels of ERK2 are elevated following the activation of
NMDARs and during the influx of calcium (Impey et al., 1999)
but are decreased by 5-HT1A-receptor activation or infusion of
an agonist of the serotonergic 5-HT1AR in the hippocampus as
Erk1/2 plays an important role in neuroprotection and synaptic
activity.
In addition to hippocampal NMDARs and 5-HT1ARs,
GABAARs play an important role in synaptic plasticity and
therefore contribute to the acquisition of fear memory.
Accordingly, drugs that modulate GABAergic transmission have
been shown to interfere with fear acquisition and extinction
(Chhatwal et al., 2005; Delamater et al., 2009; Oliveira et al.,
2009).
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Activation of GABAARs Impairs Acquisition
of Conditioned Suppression. Their
Inactivation, Before FfB Treatment,
However, didn’t Prevent the Spontaneous
Recovery
We observed that conditioned suppression was impaired in
the subgroups treated with Sintocalmy R© or diazepam, and this
impairment appeared to be related to the downregulation of
Grin2a expression in the DH. The pharmacological properties
and behavioral actions of benzodiazepines, such as amnesic,
sedative, and antianxiety effects, on GABAARs appear to be
mediated by the α1 subunit, which is preferentially located in
interneurons of forebrain areas (Collinson et al., 2002). However,
evidence has demonstrated that the GABAAR α5 subunit is
highest in the hippocampus compared with deep cortical layers
and the amygdala (Rudolph andMöhler, 2014), where it mediates
memory formation (Yee et al., 2004; Rudolph and Möhler,
2006; Atack, 2011) and is involved in learning and memory
tasks (Harris and Westbrook, 1998; Collinson et al., 2002,
2006). Although Gabra5 expression was not modulated in rats
subjected to fear conditioning with or without FfB treatment
or to the acquisition of conditioned suppression following FfB
treatment, rats treated with picrotoxin displayed upregulation
of Gabra5 expression and showed acquisition of memory. In
addition to the role of the α5 subunit in the acquisition of
fear memory, its modulation in the DH after extinction of fear
memory is supported by data from the subgroups treated with
picrotoxin+FfB; these data suggest that the α5 subunit is not
correlated with spontaneous recovery. Thus, our data reveal a
central role of the α5 subunit of the GABAAR in the acquisition
of conditioned emotional suppression, as evaluated by the lick
response. The memory-enhancing effects of benzodiazepine site
partial inverse agonists have been shown (Yee et al., 2004).
CONCLUSION
The major fear memory/treatment-dependent changes observed
in our study included the spontaneous recovery of fear memory,
which may be related to the enhancement of consolidation
of fear memory. No anti-anxiety effects were observed after
treatment with FfB. Furthermore, for the first time, we showed
that the spontaneous recovery of fear memory may be correlated
with the combined activation of GluN2A-containing NMDARs,
and 5-HT1ARs in the DH, which, in turn, modulates ERK1/2
activity. Finally, the results from gene expression analysis in
the DH and the results showing the modulatory effects of FfB
treatment indicate that the DH appears to anatomically and
functionally subserve other structures involved in the acquisition
and extinction of fear memory formation, such as the amygdala
and the prefrontal cortex. Together, our data provide important
information concerning the molecular basis of fear-conditioned
suppression and the role of the DH in these processes,
and our results suggest that FfB may represent a potential
therapeutic target for preventing or treating neurocognitive
impairments.
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